Investors & Media
Dedicated to delivering long-term investment value.
Featured News: CSL and uniQure Win 2023 Prix Galien USA Award
At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.
Press Releases
Subscribe to receive breaking news alerts about uniQure.
Subscribe-
-
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
-
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
Stock Information
Updated stock ticker information for uniQure
- NASDAQ:
- Price:
- Change:
- Volume:
(Updated every 15 minutes)
SEC Filings
Security and exchange commission filings for uniQure, including quarterly and annual reports
Learn MoreUpcoming Webcasts
No webcasts scheduled. Check back soon.
Webcast Archive
-
uniQure Huntington's Disease Update - AMT-130
View Webcast
8:30 a.m. ET -
2024 RBC Capital Markets Global Healthcare Conference
View Webcast
2:35 p.m. ET - 3:00 p.m. ET -
Leerink Partners Global Biopharma Conference
View Webcast
3:40 p.m. ET - 4:10 p.m. ET
Investor Presentations
-
July 2024 Huntington's Disease Program Update AMT-130 – Webcast Presentation
View Presentation -
Corporate Presentation – May 2024
View Presentation -
Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancements
View Presentation -
Gene Therapy Information
View Presentation